Innovent Biologics’ mazdutide and Sciwind Biosciences’ ecnoglutide entered China’s face-to-face National Reimbursement Drug List negotiations on September 5, according to local coverage of the first day’s GLP-1 session. Representatives for Innovent and Pfizer were identified at the venue. The event moves both products deeper into the access process; final price and listing terms remain to be set. (Yicai Global)
That makes the commercial trade straightforward. A national listing can expand the insured patient pool, hospital access and prescription volume. The negotiated payment standard can reduce revenue per patient. Until the final product terms arrive, the important investor question is whether volume can outrun the price concession.
Eligibility clears the first access gate
China’s National Healthcare Security Administration has repeatedly separated eligibility from inclusion. Its 2026 negotiation notice says that passing preliminary review and entering negotiation remains distinct from placement on either the basic or commercial reimbursement list. The September 5 development is therefore a process milestone, with product terms still to come.
The products also carry different corporate exposures. Mazdutide was originally developed by Eli Lilly, with Innovent holding Chinese development and commercialisation rights. Innovent’s product announcement records approval for chronic weight management in June 2025 and for glycaemic control in adults with type 2 diabetes in September 2025.
Ecnoglutide remains a Sciwind product, while Pfizer holds exclusive mainland-China commercialisation rights. Pfizer’s February agreement valued the arrangement at up to $495 million, including upfront, regulatory and sales milestones. Ecnoglutide was approved for adult type 2 diabetes in January and long-term adult weight management in March, according to the company.
The final price will decide the access bargain
The NHSA pricing mechanism says payment standards for exclusive drugs weigh clinical value, fund affordability and market scale. Manufacturers then supply designated institutions at no more than the agreed standard. That creates a measurable two-variable outcome for both companies: covered patients and net price per treatment.
The policy backdrop favours access. An official September briefing called for faster, more affordable access to innovative medicines and pointed to commercial insurance for important drugs outside basic coverage. That direction can broaden the addressable market; product-specific payment scope and volume terms remain undisclosed.
The 2026 work plan places on-site confirmation before directory compilation and schedules publication for October or November. The directory and associated price terms are the next settling records. They will show whether mazdutide and ecnoglutide won broad indications at discounts their manufacturers can support, or gained access on narrower economics.